Skip to main content
SpringerLink
Log in

The short, the long and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Bronchodilators are the cornerstone of symptomatic treatment for all chronic obstructive pulmonary disease (COPD) severity stages when administered on a regular basis to prevent or reduce symptoms and exacerbations. The principal inhaled bronchodilator treatments are beta-2 agonists and anticholinergics, used singularly or in combination. There is good evidence that regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators. Long-acting agents include the twice-daily beta-2 agonists formoterol and salmeterol, the once-daily anticholinergic tiotropium, and, more recently, the once-daily beta-2 agonist indacaterol. Long-acting bronchodilators have been shown to improve multiple clinical outcomes in COPD in comparison to short-acting agents including lung function, symptoms, dyspnea, quality of life, and exacerbations. Studies of head-to-head comparisons of long-acting bronchodilators are scant but indicate superior bronchodilation of tiotropium over salmeterol, while preliminary data from trials with the novel once-daily beta-2 agonist indacaterol indicate superior bronchodilation and clinical efficacy over twice-daily long-acting beta-2 agonists and at least equipotent bronchodilation as once-daily tiotropium. These recent therapeutic developments in COPD represent a change of paradigm with a shift from short-acting bronchodilators with multiple dosing per day to reduced dosing frequency and prolonged duration of action including once-daily treatment. This review summarizes relevant data and landmark studies comparing the efficacy of short-acting versus longer-acting bronchodilators in COPD, including new data for once-daily indacaterol, and discusses potential mechanism underlying the improved efficacy of long-acting versus short-acting bronchodilators.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2008 update. Available at: www.goldcopd.org. Accessed March 1, 2010.

  2. Sin DD, MacAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA. 2003;290:2301–2312.

    Article  PubMed  CAS  Google Scholar 

  3. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249–259.

    Article  PubMed  CAS  Google Scholar 

  4. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–1178.

    Article  PubMed  CAS  Google Scholar 

  5. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948–955.

    Article  PubMed  CAS  Google Scholar 

  6. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831–838.

    Article  PubMed  CAS  Google Scholar 

  7. Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943.

    Article  PubMed  CAS  Google Scholar 

  8. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med. 1986;315:735–739.

    Article  PubMed  CAS  Google Scholar 

  9. Braun SR, Levy SF, Grossman J. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med. 1991;91:28S–32S.

    Article  PubMed  CAS  Google Scholar 

  10. Ikeda A, Nishimura K, Koyama H, Tsukino M, Mishima M, Izumi T. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax. 1996;51:48–53.

    Article  PubMed  CAS  Google Scholar 

  11. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedmann MA. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. Chest. 1996;110:62–70.

    Article  PubMed  CAS  Google Scholar 

  12. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA. 1994;272:1497–1505.

    Article  PubMed  CAS  Google Scholar 

  13. Imhof E, Elsasser S, Karrer W, Grossenbacher M, Emmons R, Perruchoud AP. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration. 1993;60:84–88.

    Article  PubMed  CAS  Google Scholar 

  14. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest. 1994;105:1411–1419.

    Article  Google Scholar 

  15. Petty TL. The combination of ipratropium and albuterol is more effective than either agent alone. Chest. 1995;107:183S–186S.

    Article  PubMed  CAS  Google Scholar 

  16. Friedman M, Serby CW, Menjoge SS, Wilson D, Hilleman DE, Witek TJ. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999;115:635–641.

    Article  PubMed  CAS  Google Scholar 

  17. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999;115:966–971.

    Article  PubMed  CAS  Google Scholar 

  18. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1994;7:103–107.

    Article  PubMed  CAS  Google Scholar 

  19. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D’Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 1995;89:357–362.

    Article  PubMed  CAS  Google Scholar 

  20. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778–784.

    PubMed  CAS  Google Scholar 

  21. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1995;8:267–271.

    Article  PubMed  CAS  Google Scholar 

  22. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957–965.

    Article  PubMed  CAS  Google Scholar 

  23. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1087–10892.

    PubMed  CAS  Google Scholar 

  24. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22:44.

    Article  PubMed  CAS  Google Scholar 

  25. Bouros D, Kottakis J, Le Gros V, Overend T, della Cioppa G, Siafakas NM. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Opin. 2004;20:581–586.

    Article  PubMed  CAS  Google Scholar 

  26. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration. 1999;66:434–439.

    Article  PubMed  CAS  Google Scholar 

  27. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.

    Article  PubMed  CAS  Google Scholar 

  28. Calverley PMA, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919.

    Article  PubMed  CAS  Google Scholar 

  29. Calverley PMA, Anderson JA, Celli BR, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.

    Article  PubMed  CAS  Google Scholar 

  30. Calverley PMA, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456.

    Article  PubMed  CAS  Google Scholar 

  31. Tashkin DP, Celli BR, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1553.

    Article  PubMed  CAS  Google Scholar 

  32. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30:472–478.

    Article  PubMed  CAS  Google Scholar 

  33. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128:1168–1178.

    Article  PubMed  CAS  Google Scholar 

  34. O’Donnell DE, Fluege T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840.

    Article  PubMed  CAS  Google Scholar 

  35. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743–1748.

    Article  PubMed  Google Scholar 

  36. Casaburi R, Mahler DA, Jones PW, et al. A longterm evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224.

    Article  PubMed  CAS  Google Scholar 

  37. Vincken W, Van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr-fs treatment with tiotropium. Eur Respir J. 2002;19:209–16.

    Article  PubMed  CAS  Google Scholar 

  38. Van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJG. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000;55:289–294.

    Article  Google Scholar 

  39. Niewoehner DE, Lapidus R, Cote C, et al. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2009;22:587–592.

    Article  PubMed  CAS  Google Scholar 

  40. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse LJ, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404.

    Article  PubMed  CAS  Google Scholar 

  41. Donohue JF, Van Noord JA, Langley SJ, Lee A, Kesten S, Towse LJ. Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. Eur Respir J. 2001;18:26s.

    Google Scholar 

  42. Briggs JDD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397–404.

    Article  PubMed  CAS  Google Scholar 

  43. Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration. 2006;73:414–419.

    Article  PubMed  Google Scholar 

  44. Vogelmeier C, Kardos P, Harar Si, Gans SJM, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med. 2008;102:1511–1520.

    Article  PubMed  Google Scholar 

  45. Beeh KM, Hederer B, Glaab T, et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J COPD. 2009;4:119–124.

    CAS  Google Scholar 

  46. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102:1033–1044.

    Article  PubMed  Google Scholar 

  47. Beeh KM, Derom EY, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel oncedaily b2-agonist, provides sustained 24-hour bronchodilator efficacy in asthma. Eur Respir J. 2007;29:871–878.

    Article  PubMed  CAS  Google Scholar 

  48. Beier J, Beeh KM, Pascoe S, Brookman L, Peachey G, Hmissi A. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009;22:492–496.

    Article  PubMed  CAS  Google Scholar 

  49. Buhl R, Pieters W, Jack D, Owen R, Kramer B, Higgins M. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. Am J Respir Crit Care Med. 2009;179:A6185.

    Google Scholar 

  50. Buhl R, Pieters W, Jack D, Owen R, Kramer B, Higgins M. Indacaterol once-daily improves dyspnea and BODE index in COPD patients: a 52-week study versus twice-daily formoterol. Eur Respir J. 2009;34(Suppl. 53):P2026.

    Google Scholar 

  51. Feldman G, Siler T, Prasad N, Owen R, Higgins M, Kramer B. Efficacy and safety of Indacaterol 150 μg once-daily in COPD: a 12-week study. Am J Respir Crit Care Med. 2009;179:A4548.

    Google Scholar 

  52. Fogarty C, Hebert J, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily provides effective 24-h bronchodilatation in COPD patients: a 26-week evaluation versus placebo and tiotropium. Eur Respir J. 2009;34(Suppl. 53):P2025.

    Google Scholar 

  53. Lotvall J, Cosio BG, Iqbal A, et al. Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium. Eur Respir J. 2009;34(Suppl. 53):P2029.

    Google Scholar 

  54. Mahler DA, Palange P, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves dyspnea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison. Eur Respir J. 2009;34(Suppl. 53):E4360.

    Google Scholar 

  55. Yorgancioglu A, Mahler DA, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J. 2009;34(Suppl. 53):P2028.

    Google Scholar 

  56. Kornmann O, Luthra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive pulmonary disease (COPD): a 26-week placebo-controlled study. Chest. 2009;136:152S.

    Google Scholar 

  57. Dahl R, Kolman P, Jack D, et al. Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol. Eur Respir J. 2009;34(Suppl. 53):E4350.

    Google Scholar 

  58. Nonikov V, Verkindre C, Jack D, et al. Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation versus placebo and formoterol. Eur Respir J. 2009;34(Suppl. 53):P2024.

    Google Scholar 

  59. Vogelmeier C, Barbon DR, Jack D, et al. Once-daily indacaterol provides effective 24-hour bronchodilation in COPD: a double-blind comparison with tiotropium. Chest. 2009;136:4S.

    Google Scholar 

  60. Taube C, Lehnigk B, Paasch K, Kirsten DK, Jorres RA, Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:216–220.

    PubMed  CAS  Google Scholar 

  61. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:227–229.

    Google Scholar 

  62. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:542–549.

    PubMed  Google Scholar 

  63. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1557–1565.

    PubMed  Google Scholar 

  64. O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993;148:1351–1357.

    PubMed  Google Scholar 

  65. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med. 2009;180:506–512.

    Article  PubMed  Google Scholar 

  66. Beeh KM, Khindri S, Drollmann AF. Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD. Eur Respir J. 2009;34(Suppl. 53):E4357.

    Google Scholar 

  67. O’Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86–94.

    Article  PubMed  CAS  Google Scholar 

  68. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4:225–236.

    Article  PubMed  Google Scholar 

  69. Liesker JJW, Van De Velde V, Meysman M, et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med. 2002;96:559–566.

    Article  PubMed  CAS  Google Scholar 

  70. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med. 2005;143:317–326.

    PubMed  CAS  Google Scholar 

  71. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591–597.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Insaf Respiratory Research Institute, Biebricher Allee 34, D-65187, Wiesbaden, Germany

    Kai M. Beeh & Jutta Beier

Authors
  1. Kai M. Beeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jutta Beier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kai M. Beeh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beeh, K.M., Beier, J. The short, the long and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Therapy 27, 150–159 (2010). https://doi.org/10.1007/s12325-010-0017-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0017-6

Keywords

Search

Navigation